Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + FOLFIRI
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Amivantamab + FOLFIRI is a combination therapy consisting of amivantamab (a bispecific antibody targeting EGFR and MET) with FOLFIRI chemotherapy (folinic acid, fluorouracil, and irinotecan). This combination has shown promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type metastatic colorectal cancer who have not previously received anti-EGFR therapy. In clinical trials, the combination demonstrated an overall response rate of 49%, median duration of response of 7.4 months, and median progression-free survival of 7.5 months. The safety profile is manageable and consistent with each individual component, without additive toxicity. Common treatment-emergent adverse events include neutropenia, rash, stomatitis, infusion-related reactions, and diarrhea.
- Other names
- amivantamab-vmjwFOLFIRIfolinic acid + fluorouracil + irinotecan
02
Targets
EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on amivantamab + FOLFIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + FOLFIRI.